Bank of New York Mellon Corp lowered its position in Amedisys Inc (NASDAQ:AMED) by 2.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 824,304 shares of the health services provider’s stock after selling 22,271 shares during the period. Bank of New York Mellon Corp’s holdings in Amedisys were worth $43,449,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LS Investment Advisors LLC increased its position in shares of Amedisys by 233.1% in the 4th quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock valued at $188,000 after buying an additional 2,494 shares in the last quarter. NorthCoast Asset Management LLC bought a new stake in shares of Amedisys in the 3rd quarter valued at $262,000. Fox Run Management L.L.C. bought a new stake in shares of Amedisys in the 4th quarter valued at $269,000. Crossmark Global Holdings Inc. bought a new stake in shares of Amedisys in the 3rd quarter valued at $341,000. Finally, Royal Bank of Canada increased its position in shares of Amedisys by 1,320.7% in the 2nd quarter. Royal Bank of Canada now owns 6,237 shares of the health services provider’s stock valued at $392,000 after buying an additional 5,798 shares in the last quarter. Institutional investors and hedge funds own 95.33% of the company’s stock.
AMED has been the subject of a number of recent analyst reports. William Blair restated an “outperform” rating on shares of Amedisys in a research report on Tuesday, November 21st. BidaskClub cut Amedisys from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a report on Friday, January 12th. Jefferies Group set a $70.00 target price on Amedisys and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, Oppenheimer increased their target price on Amedisys from $68.00 to $63.00 and gave the stock an “outperform” rating in a report on Thursday, March 1st. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $63.18.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, February 27th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). The firm had revenue of $404.24 million for the quarter, compared to the consensus estimate of $394.96 million. Amedisys had a return on equity of 15.14% and a net margin of 1.98%. During the same quarter last year, the company posted $0.44 EPS. equities analysts forecast that Amedisys Inc will post 3 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2018/03/12/amedisys-inc-amed-position-lowered-by-bank-of-new-york-mellon-corp.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.